Ask AI
ProCE Banner Activity

EMBER-3 Patient-Reported Outcomes: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After PD on Previous ET (Marketing Campaign)

Conference Coverage
Slideset

In the phase III EMBER-3 trial, patient-reported global health score/QoL and functional domains remained stable with imlunestrant with or without abemaciclib and vs SoC ET in patients with ER+/HER2- advanced breast cancer following progression on previous endocrine therapy.

Released: June 02, 2025

Share